semaglutide sglt2 inhibitor Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application SGLT2 Inhibitors in the Management

The assessed variables were total prostate-specific antigen, prostate volume, peak systolic velocity, end-diastolic velocity, resistive index of cavernosal penile arteries, nocturnal penile tumescence, total and free testosterone, prolactin, luteinizing hormone, International Index of Erectile Function score, Depression Melancholia Scale score, fatigue scale score, and incidence of side effects

Merecz A, Markiewicz L, Sliwinska A, Kosmalski M, Kasznicki J, Drzewoski J, et al

Some patients qualify because excess weight is contributing to conditions such as high blood pressure, prediabetes, type 2 diabetes, sleep apnea, or joint discomfort

Kidney International Reports

Yes, the combined appetite suppression from both drugs can theoretically create unsafe caloric restriction